Cardiology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Cardiology Search

Cardiology

Cardiology

Home News Diseases Conferences Special Reports Multimedia

Risk factors for CAD, stroke in adults with congenital heart disease

11 hours ago

Among ageing adult congenital heart disease (ACHD) patients, traditional atherosclerotic risk factors are associated with coronary artery disease (CAD), while ischaemic stroke is related to factors suggesting a cardioembolic aetiology, a multicentre case–control study has found.

Semaglutide + standard of care encourages weight loss in patients with T2D and high CV risk

Roshini Claire Anthony, Yesterday

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Repeated yearly exposure to exercise training improves BP, MetS evolution

Yesterday

There is a need for at least 2 consecutive years of 4-month aerobic interval training to chronically enhance metabolic syndrome (MetS; z score), a recent study has found. Blood pressure (BP) that does not fully revert to pretraining values mediates this chronic effect, allowing a cumulative improvement.

Low-level silica exposure ups overall, cause-specific mortality risk

Yesterday

Low-level occupational exposure to crystalline silica is associated with increased risk of mortality from respiratory diseases, pulmonary heart disease, lung cancer and ischaemic heart disease, among other complications, a new study has found.

Peripheral, not central, BP correlates better with hypertensive target organ damage

2 days ago

The presence of target organ damage (TOD) in hypertension is more likely to result in blood pressure (BP) elevation, independently of the type of measurement (office or ambulatory, central or peripheral), according to a recent study. Central BP, even monitored during 24 hours, is not better correlated with TOD than peripheral BP.

Original New Drug Application Approvals by US FDA (1- 15 September 2017)

5 days ago

New drug applications approved by US FDA as of 1 - 15 September 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Optimizing medical treatment for symptomatic angina: What’s new, what’s hot?

Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 31 Aug 2017

Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.

Addressing the barriers to optimal use of out-of-office blood pressure monitoring

23 Aug 2017

Results from a survey presented at the 2017 Asia Pacific Society of Cardiology Congress indicate that 98% of respondents involved in managing patients with hypertension in Singapore recommend home blood pressure monitoring (HBPM) to patients with hypertension. However, a number of barriers remain to the effective use of out-of-office blood pressure (BP) monitoring.

Optimizing the management of stable CAD and HF

Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 12 Jul 2017

Coronary artery disease (CAD) is the leading cause of death worldwide and is expected to remain so for the foreseeable future due to both the ageing population and the increasing prevalence of risk factors such as hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk factor in the development of heart failure (HF). At the 2^ndAsia Pacific CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of international and regional experts discussed current strategies for managing stable CAD and HF and highlighted areas where patient outcomes may be improved.

Making clinical decisions in hypertension

25 May 2017

At a recent lunch symposium during the 14^th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.

Focus on CV Safety of NSAIDs

24 Apr 2017

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and inflammation in patients with arthritis, but the vascular effects of some NSAIDs have cast doubt on whether they can be used in patients at risk for cardiovascular (CV) disease. At the American Heart Association’s Scientific Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs nonselective NSAIDs.

Novel Approaches in the Treatment of Dyslipidaemia and T2DM

16 Mar 2017

Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.

Systemic sclerosis-related pulmonary hypertension in an era of new therapies

07 Mar 2017

At the 17^th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.

Routine use of supplemental oxygen does not improve survival in MI patients

Dr. Joseph Delano Fule Robles, 06 Sep 2017

The practice of giving oxygen to patients with MI is challenged by a recent registry-based randomized clinical trial showing that this widely accepted practice does not improve survival, according to results presented at the European Society of Cardiology Congress 2017 (ESC 2017) held in Barcelona, Spain.

Dual antithrombotic therapy an option for AF patients undergoing PCI

Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y₁₂ inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y₁₂ inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

Anacetrapib reduces major coronary events in high-risk CVD patients

Elaine Tan, 05 Sep 2017

Late-breaking results from a multinational trial show for the first time that adding anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, to intensive statin therapy reduces cardiovascular (CV) events in high-risk patients, with the possibility of providing greater benefit with longer duration of treatment.

Blocking PCSK9 synthesis with siRNA shows promise in LDL-C lowering

Jackey Suen, 04 Sep 2017

Blocking the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) with one to two injections of small interfering RNA (siRNA) provides sustained LDL-cholesterol (LDL-C) lowering for up to 1 year in patients with high cardiovascular (CV) risk and elevated LDL-C levels, the phase II ORION-1 study has shown.

Drug-specific effects of NSAIDs on BP may impact CV risk

Naomi Rodrig, 04 Sep 2017

Late-breaking data presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain have shown that ibuprofen is associated with greater increase in blood pressure (BP) than celecoxib or naproxen in patients with arthritis, potentially increasing their risk of cardiovascular (CV) events. [Eur Heart J 2017, doi: 10.1093/eurheartj/ehx508]

Ultra-low LDL-cholesterol cuts CV risk with no safety concerns

Naomi Rodrig, 04 Sep 2017

Very aggressive reduction of LDL-cholesterol with the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab was associated with progressively fewer cardiovascular (CV) events without compromising safety in patients with established atherosclerotic disease, according to a secondary analysis of the FOURIER trial (Further Cadiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) presented recently at the European Society of Cardiology Congress 2017 in Barcelona, Spain. [Lancet 2017, doi: 10.1016/S0140-6736(17)32290-0]

Catheter ablation reduces mortality in patients with heart failure and AF

Jenny Ng, 04 Sep 2017

Landmark results from the CASTLE-AF trial has demonstrated that catheter ablation significantly improves outcomes in patients with heart failure and atrial fibrillation (AF), reducing the risk of all-cause mortality and hospitalizations for worsening heart failure by more than one-third compared with conventional treatment.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!

DOWNLOAD